What is DefiniGEN?
DefiniGEN specializes in providing advanced human-derived induced pluripotent stem cell (iPSC) disease models, focusing on metabolic and rare diseases. Their comprehensive services include efficacy and toxicology screening, gene editing, and the development of specific disease models such as MASLD and Wilson's Disease. Serving a clientele that spans top pharmaceutical companies, biotechnology firms, and research institutions, DefiniGEN is dedicated to delivering scalable and predictive liver and metabolic disease models. With over 13 years of experience, the company leverages proprietary iPSC technologies to accelerate scientific discovery.
How much funding has DefiniGEN raised?
DefiniGEN has raised a total of $6.1M across 2 funding rounds:
Series A
$3.8M
Private Equity
$2.3M
Series A (2014): $3.8M with participation from Cambridge Enterprise and 24 Haymarket
Private Equity (2016): $2.3M led by Cambridge Enterprise
Key Investors in DefiniGEN
Cambridge Enterprise
Cambridge Enterprise is the commercialization arm of the University of Cambridge, investing in and supporting spin-out companies and academic ventures. Their focus is on leveraging cutting-edge research and technology from the university.
24 Haymarket
24 Haymarket is a private network of investors and operators focused on capital investment in ventures. They partner with entrepreneurs to provide funding and strategic support for business growth.
What's next for DefiniGEN?
The recent major strategic investment positions DefiniGEN for significant expansion and further development of its iPSC disease modeling platform. This capital infusion is expected to fuel advancements in their service offerings, potentially broadening their reach into new therapeutic areas or enhancing their existing disease models. The company's focus on serving the pharmaceutical and biotechnology sectors suggests a strategic direction aimed at becoming a key partner in drug discovery and development pipelines, driving innovation in the treatment of metabolic and rare diseases.
See full DefiniGEN company page
